RTI Surgical has received a close-out letter from the Food and Drug Administration (FDA) verifying effective implementation of the corrective actions put in place following the warning letter the company received in October 2012.
BioAdapt® Bridge is an allograft solution with a large graft cavity designed to fill bony voids and defects. Offered in two sizes, the graft is cohesive and moldable and can be easily filled with autograft or allograft.
The Tritium SCP System enhances the stability and strength of traditional sternal closure techniques by using a unique load-sharing concept.
Acquisition creates a global surgical implant company positioned for growth in orthopedics and biologics
Fortiva™ Porcine Dermis is sterilized through the Tutoplast® Tissue Sterilization Process, is ready-to-use and is available in a broad array of sizes. The implant makes RTI the only provider with a comprehensive biologic solutions portfolio for use in hernia repair procedures.
Who Are We?
RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to advancing science, safety and innovation, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of Advamed.